Thrombopoin‐promoting drugs are the preferred second‐line treatment for ITP, including recombinant human thrombopoietin (rhTPO), atratropipin, and romitastatin, all supported by prospective multicenter randomized controlled clinical data. The gene discussed is THPO; the disease is autoimmune thrombocytopenic purpura.